Metabolic atrophy and 3‐T 1H‐magnetic resonance spectroscopy correlation after radiation therapy for prostate cancer. (20th February 2014)

• Record Type: Journal Article
• Authors: Panebianco, Valeria; Barchetti, Flavio; Musio, Daniela; Forte, Valerio; Pace, Alberto; De Felice, Francesca; Barchetti, Giovanni; Tombolini, Vincenzo; Catalano, Carlo
• Is Part Of: BJU international. Volume 114:Number 6(2014:Dec.)
• Page Start: 852
• Page End: 859
• Publication Date: 2014-02-20
• Subjects: Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.12553
• Languages: English
• ISSNs: 1464-4096

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bju12553-sec-0001" sec-type="section"> <title>Objective</title> <p>To correlate 3‐T magnetic resonance spectroscopic imaging (MRSI) with prostate‐specific antigen (PSA) levels in patients with prostate cancer treated with external beam radiation therapy to assess the potential advantages of MRSI.</p> </sec> <sec id="bju12553-sec-0002" sec-type="section"> <title>Materials and Methods</title> <p>A total of 50 patients (age range 65–83 years) underwent PSA and MRSI surveillance before and at 3, 6, 12, 18 and 24 months after radiotherapy.</p> </sec> <sec id="bju12553-sec-0003" sec-type="section"> <title>Results</title> <p>Of the 50 patients examined, 13 patients completely responded to therapy showing metabolic atrophy (MA), defined as a choline‐plus‐creatine/citrate (CC/C) ratio <0.2, at 3 months; in this group none had biochemical relapse (PSA nadir + 2 ng/mL) by the end of the follow‐up.</p> <p>Of the 50 patients, 35 showed a partial response to therapy (CC/C ratio between 0.2 and 0.8) at 3 and 6 months and, of these 35 patients, 30 reached MA at 12 months, while five developed a recurrence (CC/C ratio >0.8).</p> <p>Three of those patients with recurrence had a biochemical relapse at 18 months and the other two at 24 months.</p> <p>Two of the 50 patients did not respond to the treatment, showing persistent disease from the 3rd month (CC/C ratio >0.8); one patient had biochemical relapse at 6 and the other at 12 months.</p> </sec> <sec id="bju12553-sec-0004" sec-type="section"> <title>Conclusions</title> <p>MRSI was shown to have a greater potential than PSA level in monitoring patients after radiotherapy, because it anticipates PSA nadir, and biochemical relapse in particular.</p> </sec> </abstract>